Health · Pharma & Biotech · 1 hr ago

Racura gets Israeli approval for first site in leukaemia drug trial

Racura gets Israeli approval for first site in leukaemia drug trial

Sheba Medical Center in Israel approved the first site for Racura Oncology’s EMILI trial of its drug RC220.

The trial will test the drug in adults with acute myeloid leukaemia that has returned or resisted treatment.

AML is an aggressive cancer of the blood and bone marrow.

Some patients may be able to receive a potentially curative stem cell transplant, but their leukaemia generally needs to be controlled first.

The trial will test whether seven days of RC220 can bring the cancer into remission and help patients proceed to transplant.

Racura expects to activate the site by the end of 2026 and enrol and treat the first patient in early 2027.

The company plans to seek approval to open more sites in Europe, the United States and Australia in 2027, and will use the trial’s early stage to help choose a dose for its Phase III stage.

1 source

Related

What people are saying

Dr Daniel TillettRacura Oncology CEO
EMILI will open first at Sheba, where Professor Arnon Nagler and his team have studied bisantrene in AML patients for many years
via Stockhead
With this approval, our focus now turns to activating Sheba with other sites to follow, with the aim of generating the data needed to select the right RC220 dose for the pivotal Phase III stage.
via Stockhead